Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 122-130 , April 2010

Targeted therapeutic approaches for hormone-refractory prostate cancer

  • Flora Stavridi

      Affiliations

    • Department of Medicine, Royal Marsden Hospital, Downs Road, Surrey SM2 5PT, UK
    • Tel.: +44 20 86426011; fax: +44 20 89156719.
    • ,
  • Eleni M. Karapanagiotou

      Affiliations

    • Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece
    • Tel.: +30 210 7475034; fax: +30 210 7781035.
    • ,
  • Kostas N. Syrigos

      Affiliations

    • Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Athens, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 210 7475034; fax: +30 210 7781035.

Received 25 January 2009 ,Revised 28 May 2009 ,Accepted 7 June 2009.

References 

  1. Cancerline UK. http://www.cancerlineuk.net/prostatecancer.
  2. American cancer society: prostate cancer statistics. http://www.cancer.org.
  3. American society of clinical oncology: prostate cancer statistics. http://www.cancer.net/prostate.
  4. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med. 1998;339:1036–1042
  5. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  6. Yoshino T, Shiina H, Urakami S, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12:6116–6124
  7. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001;19:2509–2516
  8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med. 2004;351:1513–1520
  9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004;351:1502–1512
  10. Berthold DR, Pond G, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. Proc ASCO Prostate Cancer Symp 2007 [abstr 147]
  11. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13:125–129
  12. Lin AM, Rosenberg JE, Weinberg VK, et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP)). J Clin Oncol. 2006;24(18S):[abstr 4558]
  13. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B Analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439–1446
  14. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol. 2007;25(18S):[abstr 5019]
  15. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–8261
  16. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 2005;23:1–9
  17. Wang YR, Wigington DP, Strugnell SA, Knutson JC. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug. Anticancer Res. 2005;25:4333–4339
  18. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997;50:999–1006
  19. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7:1043–1051
  20. Moffatt KA, Johannes WU, Miller GJ. 1α,25-dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999;5:695–703
  21. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21:123–128
  22. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol. 2007;25:669–674
  23. Beer TM, Venner PM, Ryan CW, et al. High dose calcitriol may reduce thrombosis in cancer patients. Brit J Haematol. 2006;135:392–394
  24. Novacea press releases. http://www.novacea.com/610.asp?id=136&nav=news.
  25. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–409
  26. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7:1932–1936
  27. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004;22:1655–1663
  28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 2004;350:2335–2342
  29. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol. 2003;22:[abstr 1578]
  30. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006;24:250–253
  31. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532–2539
  32. Ning YM, Arlen PM, Gulley JL, et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol. 2008;26(May 20 suppl.):[abstr 5000]
  33. Moss RA, Mohile SG, Shelton G, Melia J, Petrylak DP. A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Proc ASCO Prostate Cancer Symp 2007 [abstr 89].
  34. Pagliaro LC, Tannir NM, Tu S, et al. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy. J Clin Oncol. 2008;26(May 20 suppl.):[abstr 13545]
  35. Garcia JA, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. J Clin Oncol. 2008;26(May 20 suppl.):[abstr 5143]
  36. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–116
  37. Montironi R, Mazzucchelli R, Barbisan F, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol. 2007;52:1682–1689
  38. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–949
  39. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12:6296s–6300s
  40. Yin JJ, Mohammad KS, Käkönen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003;100:10954–10959
  41. Bagnato A, Salani D, Di Castro V, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 1999;59:720–727
  42. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond). 2002;103(Suppl. 48):302S–305S
  43. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab. 2003;14:44–50
  44. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther. 1996;276:473–481
  45. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–689
  46. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959–1966
  47. Vogelzang NJ, Nelson JB, Schulman CC, et al. Meta-analysis of clinical trials of atrasentan 10mg in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23(June 1 suppl.):[abstr 4563]
  48. Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007;67:3818–3826
  49. Moore CN, Creel P, Petros W, et al. Phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol. 2006;24(June 20 suppl.):[abstr 14504]
  50. http://clinicaltrials.gov/ct2/show/NCT00134056.
  51. Tudor G, Aguilera A, Halverson DO, Laing ND, Sausville EA. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000;7:574–586
  52. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 1997;89:1027–1036
  53. Tamm I, Schriever F, Dörken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol. 2001;2:33–42
  54. Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005;11:3854–3861
  55. http://clinicaltrials.gov/ct2/show/NCT00085228.
  56. Sternberg CN, Dumez H, Van Poppel H, et al. Multicenter randomized EORTC trial 30021 of docetaxel+oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC). Proc ASCO Prostate Cancer Symp 2007 [abstr 144].
  57. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95–98
  58. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50:179–188
  59. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287–1296
  60. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008;14:833–839
  61. Chi KN, Hotte SJ, Yu E, et al. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol. 2007;25(June 20 suppl.):[abstr 5069]
  62. Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int; 2008 Mar 10 [Epub ahead of print].
  63. Saad FS, Hotte J, North SA, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol. 2008;26(May 20 suppl.):[abstr 5002]
  64. Neckers L. Heat shock protein 90 inhibition: a novel therapeutic approach to affect androgen receptor function in prostate cancer. ASCO 2007 educational book.
  65. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002;8:986–993
  66. Karapanagiotou E, Syrigos KN, Saif MW. Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Invest Drugs. 2009;18(2):1–14
  67. Syrigos KN, Harrington KJ, Karayiannakis AJ, et al. Clinical significance of heat shock protein-70 expression in bladder cancer. Urology. 2003;61:677–680
  68. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis. 2003;8:61–70
  69. Rocchi P, So A, Kojima S, Signaevsky M, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004;64:6595–6602
  70. Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anticancer Res. 2006;26:1583–1587
  71. Zoubeidi A, Zardan A, Beraldi E, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 2007;67:10455–10465
  72. http://clinicaltrials.gov/ct2/show/NCT00487786.
  73. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003;95:458–470
  74. Lin AM, Rini BI, Weinberg V, et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006;98:763–769
  75. Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004;22:3323–3329
  76. Mathew P, Thall PF, Johnson MM, et al. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). J Clin Oncol. 2006;24:[abstr 4562]
  77. Di Lorenzo G, Tortora G, D’Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8:3438–3444
  78. Festuccia C, Muzi P, Millimaggi D, et al. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer. 2005;12:983–998
  79. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res. 2002;8:3870–3876
  80. Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005;23:455–460
  81. Small EJ, Fontana J, Tannir N, et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007;100:765–769
  82. Salzberg M, Rochlitz C, Morant R, et al. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie. 2007;30:355–360
  83. Whang YE, Moore CN, Armstrong AJ, et al. A phase II trial of lapatinib in hormone refractory prostate cancer. J Clin Oncol. 2008;26:[abstr 16037]
  84. Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate. 2008;68:935–944
  85. Yano S, Matsuyama H, Hirata H, et al. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006;15:1453–1460
  86. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol. 2005;23:8262–8269
  87. Vieweg J. Immunotherapy for advanced prostate cancer. Rev Urol. 2007;S29–S38
  88. Mendiratta P, Armstrong AJ, George DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol. 2007;9:S9–S19
  89. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894–3903
  90. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–3094
  91. Bonnotte B, Gough M, Phan V, et al. Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Res. 2003;63:2145–2149
  92. http://www.nwbio.com/clinical_dcvax_prostate.php.
  93. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543
  94. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883–3891
  95. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:975–984
  96. http://clinicaltrials.gov/show/NCT00089856.
  97. http://clinicaltrials.gov/show/NCT00133224.
  98. Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostat Dis. 2009;12:13–16
  99. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008;26:2862–2870

PII: S0305-7372(09)00088-7

doi: 10.1016/j.ctrv.2009.06.001

Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 122-130 , April 2010

Article Tools

* Image Usage & Resolution